Abciximab(ab six’ ah mab)
ReoPro
PREGNANCY CATEGORY C
Drug Classes
Antiplatelet
Glycoprotein IIb/IIIa inhibitor
Therapeutic Actions
Interferes with platelet membrane function by inhibiting fibrinogen binding and platelet–platelet interactions; inhibits platelet aggregation and prolongs bleeding time; effect is irreversible for life of the platelet.
Indications
Adjunct to percutaneous coronary intervention (PCI) for the prevention of cardiac ischemic complications in patients undergoing PCI and with unstable angina not responding to conventional therapy when PCI is planned within 24 hr; intended to be used with heparin and aspirin therapy
Unlabeled uses: Early treatment of acute MI or acute ischemic stroke
Contraindications and Cautions
Contraindicated with allergy to abciximab; neutropenia; thrombocytopenia (fewer than 100,000 cells/mcL); hemostatic disorders; bleeding ulcer; intracranial bleeding; major trauma; vasculitis; recent major surgery; aneurysm; use of IV dextran (before or during PCI); pregnancy; severe, uncontrolled hypertension; active internal bleeding; recent (within 6 wk) GI or GU bleeding; history of stroke within 2 yr; administration of oral anticoagulants within 7 days (unless PT is 1.2 times control or less).
Use cautiously during lactation and with concurrent use of anticoagulants, thrombolytics, or antiplatelet drugs.
Available Forms
Injection—2 mg/mL
Dosages
Efficacy of abciximab has only been studied in combination with heparin and aspirin.
Adults
Adjunct to PCI: 0.25 mg/kg by IV bolus 10–60 min prior to procedure, followed by continuous infusion of 0.125 mcg/kg/min (maximum dose 10 mcg/min) for 12 hr.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
